Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis

The OlympiAD Phase III study (NCT02000622) established the clinical benefits of olaparib tablet monotherapy (300 mg twice daily) over chemotherapy treatment of physician’s choice (TPC) in patients with a germline BRCA1/2 mutation (gBRCAm) and human epidermal growth factor receptor 2 (HER2)-negative...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Sci Rep
Hoofdauteurs: Im, Seock-Ah, Xu, Binghe, Li, Wei, Robson, Mark, Ouyang, Quchang, Yeh, Dah-Cherng, Iwata, Hiroji, Park, Yeon Hee, Sohn, Joo Hyuk, Tseng, Ling-Ming, Goessl, Carsten, Wu, Wenting, Masuda, Norikazu
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Nature Publishing Group UK 2020
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7260217/
https://ncbi.nlm.nih.gov/pubmed/32472001
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-63033-4
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items